Additionally, more research could be conducted to confirm the downstream genetic targets of the KDM2A/TGF-β/Smad pathway and the KDM2A/JAG1 axis in GBM and glioma to improve treatments and mitigate their secondary effects in patients. This evidence concerns the gene JAG1 and central nervous system cancer.